TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05012371
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03949478
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
Study: NCT05012371
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04522180
Drug: GHR-LRX
Normalized name: Akcea ttr lrx
DrugBank: Eplontersen (DB16199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHR-LRX was administered by SC injection.
Study: NCT05842785
Drug: Phase I dose escalation
Normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT00206193
Drug: mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00206193
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00206193
Drug: sulprostone
Normalized name: sulprostone
DrugBank: Sulprostone (DB12708)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05986851
Drug: Azeliragon
Normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05177029
Drug: Lu AG06466
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG06466 will be administered per schedule specified in the arm.
Study: NCT06333210
Drug: Adalimumab subcutaneous injection
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous injection
Study: NCT05681390
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
Study: NCT06441214
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be treated with Zanubrutinib as per routine clinical practice.
Study: NCT05480280
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
Study: NCT05480280
Drug: Oxaliplatin injection
Normalized name: oxaliplatin Injection
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m², ivdrip, D1
Study: NCT05480280
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
Study: NCT05480280
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
Study: NCT05470075
Drug: Tramadol hydrochloride SR Tablets
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
Study: NCT05995405
Drug: GTX-104
Normalized name: toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine IV infusion
Study: NCT05955885
Drug: Difflam
Normalized name: Difflam Eucalyptus and Menthol Flavour
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
Study: NCT05082545
Drug: SHR-2002 and SHR-1316
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort study
Study: NCT05971199
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
Study: NCT05971199
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab: 200 mg i.v. every 3 weeks
Study: NCT05903716
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
Study: NCT04898712
Drug: Tranexamic Acid 500 MG
Normalized name: tranexamic acid 500 MG
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid 500mg oral tablets
Study: NCT04491370
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
Study: NCT05990868
Drug: Tylenol
Normalized name: Tylenol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tylenol will be placed at the time of oocyte retrieval
Study: NCT05238064
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years.
Study: NCT05238064
Drug: CHOP
Normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
Study: NCT05272254
Drug: 10% povidone iodine + FV
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied to children's teeth
Study: NCT05897307
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexmedetomidine
Study: NCT06158009
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06481852
Drug: MTT with antibiotic preconditioning + fiber supplementation
Normalized name: fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study: NCT05903313
Drug: Chang Gung ECG Abnormality Detection Software
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
Study: NCT05876221
Drug: Cablivi
Normalized name: Cablivi
DrugBank: Caplacizumab (DB06081)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
Study: NCT05699603
Drug: Calcipotriene
Normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied topically
Study: NCT06721247
Drug: Magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral intake of magnesium for asthmatic patients with dose 200 mg per day for one year in addition to usual asthmatic treatment according to GINA guidelines 2024
Study: NCT05181839
Drug: Burosumab
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
Study: NCT05196256
Drug: Sufentanyl/Levobupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural analgesia
Study: NCT04783389
Drug: CBP-201
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP-201 subcutaneous (SC) injection.
Study: NCT05886465
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg, iv.drip, Q3W
Study: NCT05886465
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg, iv.drip, Q3W
Study: NCT05217758
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg/day, once daily, 7 days
Study: NCT04887857
Drug: CC-486
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04887857
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05434559
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch during standard routine care to Insulin Degludec.
Study: NCT06112223
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
Study: NCT06112223
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive oral tramadol 100 mg 1 hour before the surgery.
Study: NCT05043402
Drug: navicixizumab
Normalized name: Navicixizumab
DrugBank: Navicixizumab (DB12634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: navicixizumab IV
Study: NCT05958160
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate is an anti-seizure medication
Study: NCT06112678
Drug: CKD-348(6)
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04511416
Drug: Metformin XR, 500-2000mg nocte
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin XR, 500-2000mg nocte
Study: NCT05016297
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: baricitinib 4mg per day
Study: NCT05016297
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 200mg twice a day
Study: NCT04789616
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of the participants will take maraviroc for a period of 8 weeks.
Study: NCT05702190
Drug: Opium tincture
Normalized name: opium tincture
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
Study: NCT05588297
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
Study: NCT05588297
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
Study: NCT05534230
Drug: Dexmedetomidine Injectable Solution
Normalized name: dexmedetomidine Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
Study: NCT05534230
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
Study: NCT00002045
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06062069
Drug: CT-868
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
Study: NCT05650164
Drug: avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as provided in real world practice
Study: NCT05650164
Drug: axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: as provided in real world practice
Study: NCT04854096
Drug: NS-018
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT05360134
Drug: Carica Papaya Leaf Extract
Normalized name: Carica papaya leaf extract
DrugBank: Papaya (DB10658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
Study: NCT05601167
Drug: nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
Study: NCT06585761
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with HF are subjected to regular dose of SGLT2I member according to patient status.
Study: NCT05776927
Drug: Salmeterol Xinafoate / Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
Study: NCT05776927
Drug: Placebo to Salmeterol Xinafoate / Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
Study: NCT05776927
Drug: Run-In Medication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
Study: NCT05386706
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional metformin monotherapy.
Study: NCT00002405
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05501470
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic
Study: NCT04375800
Drug: Doravirine
Normalized name: Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
Study: NCT06131957
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
Study: NCT05456854
Drug: Kisspeptin-10
Normalized name: Kisspeptin-10
DrugBank: Kisspeptin-10 (DB16210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of kisspeptin-10 \* 16 hr
Study: NCT01217697
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
Study: NCT05681039
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05681039
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT04636515
Drug: F520
Normalized name: F520
DrugBank: Rulonilimab (DB18922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg，Q3W
Study: NCT05832320
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
Study: NCT05832320
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
Study: NCT06232005
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of antifibrotic drugs in urethral strictures after internal urethrotomy
Study: NCT00816205
Drug: Coated Nifedipine Suppositories
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine.
Study: NCT04999020
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Study: NCT06549270
Drug: MAbs
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly or quarterly mAbs administration
Study: NCT05363839
Drug: ACH-000029
Normalized name: ACh
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACH-000029 will be administered orally via a capsule.
Study: NCT04697602
Drug: Stepwise dose titration of febuxostat and low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
Study: NCT04697602
Drug: Fixed dose febuxostat and low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
Study: NCT05028322
Drug: IMIQUIMOD cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cream to apply before intra-dermal vaccine injection
Study: NCT04748705
Drug: IMC-1
Normalized name: IMC-1C11
DrugBank: IMC-1C11 (DB06101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Study: NCT05084638
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg subcutaneous injection
Study: NCT05444374
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-PD-1 humanized monoclonal antibody injection
Study: NCT05444374
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized anti-VEGF monoclonal antibody injection